Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.

Yushi Naito,Masashi Kato,Hideji Kawanishi,Akiyuki Yamamoto,Fumitoshi Sakamoto,Hiroki Hirabayashi, Masataka Kobayashi,Yoshihisa Matsukawa,Tohru Kimura, Hidemori Araki,Toshinori Nishikimi,Atsuya Kondo,Yasushi Yoshino, Yoshimasa Hashimoto,Yojiro Nakano,Toyonori Tsuzuki

The Prostate（2022）

引用 2|浏览2

暂无评分

摘要

The findings highlight a high prevalence of IDC-P among patients with mHSPC and suggest that IDC-P positivity may be a reliable indicator that ARAT should be implemented as first-line treatment.

查看译文

关键词

androgen receptor axis-targeted agent,pathological predictor,response to therapy,upfront therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要